Parkinson’s disease is primarily diagnosed through clinical assessment, while reliable, non-invasive biochemical biomarkers remain an important unmet need.
A September 2026 study published in *npj Parkinson’s Disease* investigated whether urinary metabolites associated with neurotransmitter metabolism could help distinguish Parkinson’s disease from healthy individuals.
Using advanced mass spectrometry, researchers identified characteristic alterations in urinary amines and phenolic metabolites.
**Key Scientific Findings**
• **Metabolomic profiling:** Analysis of 63 participants identified 196 annotated urinary metabolites, including 143 amines and 49 phenolic compounds.
• **Biochemical alterations:** Parkinson’s disease was associated with increased dopamine 3-O-sulfate and reduced tryptophan-related metabolites, suggesting altered neurotransmitter metabolism.
• **Candidate biomarker panel:** A three-metabolite signature demonstrated an area under the ROC curve (AUC) of 0.923 for distinguishing Parkinson’s disease from healthy controls.
• **Analytical innovation:** Chemical derivatization combined with ion-mobility mass spectrometry enabled more detailed characterization of selected urinary metabolites.
**Clinical Biochemistry Perspective**
Urine offers a non-invasive matrix for investigating systemic biochemical changes associated with neurodegenerative diseases.
However, this preliminary study included only 21 patients with Parkinson’s disease. The biomarker panel requires larger, independent validation cohorts before its diagnostic utility can be established.
**The broader implication:** Metabolomic profiling may expand clinical biochemistry beyond conventional single-analyte measurements toward integrated molecular signatures of neurological disease.
**Reference:** Li Z, Cui P, Zhang L, et al. *Decoding the metabolic landscape of Parkinson’s disease: dansylated urinary amines and phenols submetabolomes for signature profiling and biomarker discovery.* npj Parkinson’s Disease. 2026.
https://doi.org/10.1038/s41531-026-01572-9
#BIOCHEMBEYOND #ClinicalBiochemistry #Metabolomics #ParkinsonsDisease #BiomarkerDiscovery #MassSpectrometry #PrecisionMedicine